Render Target: STATIC
Render Timestamp: 2024-12-13T11:40:44.803Z
Commit: 611277b6de3cd1bb065350b6ef8d63df412b7185
XML generation date: 2024-08-01 15:27:16.724
Product last modified at: 2024-11-07T13:00:14.855Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

LAT1 Antibody #5347

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 39
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    LAT1 Antibody detects endogenous levels of total LAT1 protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues at the amino terminus of human LAT1 protein. Antibodies were purified by protein A and peptide affinity chromatography.

    Background

    L-type amino acid transporter 1 (LAT1), also known as solute carrier family 7 member 5 (SLC7A5), is a high-affinity neutral transporter of larger amino acids. It facilitates the cellular amino acid uptake in a sodium independent manner (1-2) and selectively transports D-and L-isomers of small neutral amino acids (3). LAT1 also regulates amino acid exchange in conjunction with solute carrier family 1 member 5 (SLC1A5) (2,4-6). Transport of thyroid hormones across the placenta is established via LAT1 during normal fetal development (7). LAT1 promotes neuronal cell proliferation by regulating the transport of amino acids across the blood brain barrier (8). LAT1 is upregulated in various cancer types, including breast cancer, lung cancer, prostate cancer, and gliomas (9,10). High expression of LAT1 is detected in non-small cell lung cancer with lymph node metastases (9,11,12). Increased LAT1 expression is a novel biomarker of high grade malignancy in prostate cancers (12). Inhibition of LAT1 suppresses tumor cell growth in several tumor types (10,13).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.